ImmuCell Stock Based Compensation vs Investments Analysis

ICCC Stock

USD 3.70 0.04 1.07%

ImmuCell financial indicator trend analysis is infinitely more than just investigating ImmuCell recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ImmuCell is a good investment. Please check the relationship between ImmuCell Stock Based Compensation and its Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

Stock Based Compensation vs Investments

Stock Based Compensation vs Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ImmuCell Stock Based Compensation account and Investments. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between ImmuCell's Stock Based Compensation and Investments is -0.28. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Investments in the same time period over historical financial statements of ImmuCell, assuming nothing else is changed. The correlation between historical values of ImmuCell's Stock Based Compensation and Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of ImmuCell are associated (or correlated) with its Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Investments has no effect on the direction of Stock Based Compensation i.e., ImmuCell's Stock Based Compensation and Investments go up and down completely randomly.

Correlation Coefficient

-0.28

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.

Most indicators from ImmuCell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ImmuCell current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.At present, ImmuCell's Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2021	2022	2023	2024 (projected)
Gross Profit	8.7M	7.6M	4.4M	3.9M
Total Revenue	19.2M	18.6M	17.5M	18.3M

Gross Profit Total Revenue

ImmuCell fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.94	0.88	0.91	0.98	0.98	0.63	-0.61	0.56	0.98	-0.06	0.17	0.95	0.88	0.94	0.75	-0.32	0.98	0.94	0.66	0.82	0.38	0.61	0.94	0.87	0.9
Short Long Term Debt Total	0.94		0.9	0.96	0.84	0.96	0.85	-0.79	0.26	0.96	0.09	-0.15	0.89	0.75	1.0	0.88	-0.24	0.94	1.0	0.42	0.92	0.21	0.51	0.98	0.76	0.79
Other Current Liab	0.88	0.9		0.86	0.81	0.87	0.71	-0.78	0.35	0.87	0.28	-0.05	0.84	0.77	0.9	0.83	-0.09	0.91	0.9	0.53	0.81	0.12	0.4	0.94	0.74	0.79
Total Current Liabilities	0.91	0.96	0.86		0.82	0.92	0.83	-0.79	0.23	0.92	0.11	-0.12	0.87	0.7	0.95	0.91	-0.21	0.93	0.97	0.46	0.93	0.28	0.63	0.96	0.73	0.77
Total Stockholder Equity	0.98	0.84	0.81	0.82		0.94	0.45	-0.46	0.72	0.93	-0.15	0.36	0.92	0.91	0.85	0.62	-0.36	0.95	0.85	0.77	0.7	0.45	0.61	0.85	0.9	0.9
Property Plant And Equipment Net	0.98	0.96	0.87	0.92	0.94		0.71	-0.64	0.46	1.0	-0.02	0.02	0.92	0.84	0.97	0.75	-0.28	0.96	0.96	0.53	0.85	0.39	0.57	0.94	0.85	0.87
Net Debt	0.63	0.85	0.71	0.83	0.45	0.71		-0.83	-0.28	0.71	0.24	-0.58	0.58	0.37	0.84	0.88	-0.11	0.65	0.85	-0.02	0.84	-0.03	0.34	0.81	0.4	0.45
Retained Earnings	-0.61	-0.79	-0.78	-0.79	-0.46	-0.64	-0.83		0.07	-0.63	-0.43	0.43	-0.63	-0.45	-0.77	-0.89	-0.14	-0.72	-0.78	-0.17	-0.85	0.14	-0.19	-0.81	-0.47	-0.53
Cash	0.56	0.26	0.35	0.23	0.72	0.46	-0.28	0.07		0.46	-0.27	0.81	0.56	0.7	0.28	-0.01	-0.23	0.54	0.27	0.83	0.14	0.46	0.31	0.31	0.67	0.64
Non Current Assets Total	0.98	0.96	0.87	0.92	0.93	1.0	0.71	-0.63	0.46		-0.04	0.02	0.92	0.84	0.97	0.75	-0.3	0.96	0.96	0.52	0.85	0.38	0.57	0.94	0.84	0.86
Non Currrent Assets Other	-0.06	0.09	0.28	0.11	-0.15	-0.02	0.24	-0.43	-0.27	-0.04		-0.42	-0.1	-0.07	0.08	0.25	0.66	0.03	0.09	-0.16	0.2	-0.05	-0.14	0.13	-0.07	-0.03
Cash And Short Term Investments	0.17	-0.15	-0.05	-0.12	0.36	0.02	-0.58	0.43	0.81	0.02	-0.42		0.18	0.34	-0.13	-0.28	-0.35	0.13	-0.13	0.76	-0.26	0.28	0.21	-0.11	0.3	0.26
Net Receivables	0.95	0.89	0.84	0.87	0.92	0.92	0.58	-0.63	0.56	0.92	-0.1	0.18		0.83	0.89	0.71	-0.3	0.95	0.89	0.65	0.78	0.27	0.56	0.92	0.81	0.85
Common Stock Shares Outstanding	0.88	0.75	0.77	0.7	0.91	0.84	0.37	-0.45	0.7	0.84	-0.07	0.34	0.83		0.76	0.54	-0.28	0.87	0.75	0.8	0.66	0.35	0.44	0.76	0.99	0.98
Non Current Liabilities Total	0.94	1.0	0.9	0.95	0.85	0.97	0.84	-0.77	0.28	0.97	0.08	-0.13	0.89	0.76		0.87	-0.24	0.94	1.0	0.44	0.9	0.23	0.53	0.98	0.77	0.8
Inventory	0.75	0.88	0.83	0.91	0.62	0.75	0.88	-0.89	-0.01	0.75	0.25	-0.28	0.71	0.54	0.87		-0.17	0.8	0.88	0.33	0.87	-0.05	0.44	0.9	0.54	0.61
Other Current Assets	-0.32	-0.24	-0.09	-0.21	-0.36	-0.28	-0.11	-0.14	-0.23	-0.3	0.66	-0.35	-0.3	-0.28	-0.24	-0.17		-0.23	-0.24	-0.3	-0.17	0.21	-0.1	-0.19	-0.22	-0.21
Other Stockholder Equity	0.98	0.94	0.91	0.93	0.95	0.96	0.65	-0.72	0.54	0.96	0.03	0.13	0.95	0.87	0.94	0.8	-0.23		0.95	0.66	0.86	0.3	0.55	0.96	0.86	0.89
Total Liab	0.94	1.0	0.9	0.97	0.85	0.96	0.85	-0.78	0.27	0.96	0.09	-0.13	0.89	0.75	1.0	0.88	-0.24	0.95		0.45	0.91	0.24	0.55	0.98	0.76	0.8
Total Current Assets	0.66	0.42	0.53	0.46	0.77	0.53	-0.02	-0.17	0.83	0.52	-0.16	0.76	0.65	0.8	0.44	0.33	-0.3	0.66	0.45		0.31	0.33	0.49	0.49	0.77	0.77
Short Term Debt	0.82	0.92	0.81	0.93	0.7	0.85	0.84	-0.85	0.14	0.85	0.2	-0.26	0.78	0.66	0.9	0.87	-0.17	0.86	0.91	0.31		0.11	0.32	0.9	0.68	0.71
Intangible Assets	0.38	0.21	0.12	0.28	0.45	0.39	-0.03	0.14	0.46	0.38	-0.05	0.28	0.27	0.35	0.23	-0.05	0.21	0.3	0.24	0.33	0.11		0.71	0.19	0.43	0.39
Accounts Payable	0.61	0.51	0.4	0.63	0.61	0.57	0.34	-0.19	0.31	0.57	-0.14	0.21	0.56	0.44	0.53	0.44	-0.1	0.55	0.55	0.49	0.32	0.71		0.53	0.51	0.52
Property Plant And Equipment Gross	0.94	0.98	0.94	0.96	0.85	0.94	0.81	-0.81	0.31	0.94	0.13	-0.11	0.92	0.76	0.98	0.9	-0.19	0.96	0.98	0.49	0.9	0.19	0.53		0.76	0.81
Common Stock Total Equity	0.87	0.76	0.74	0.73	0.9	0.85	0.4	-0.47	0.67	0.84	-0.07	0.3	0.81	0.99	0.77	0.54	-0.22	0.86	0.76	0.77	0.68	0.43	0.51	0.76		1.0
Common Stock	0.9	0.79	0.79	0.77	0.9	0.87	0.45	-0.53	0.64	0.86	-0.03	0.26	0.85	0.98	0.8	0.61	-0.21	0.89	0.8	0.77	0.71	0.39	0.52	0.81	1.0

Click cells to compare fundamentals

ImmuCell Account Relationship Matchups

ImmuCell fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	38.7M	40.4M	44.5M	44.9M	43.8M	46.0M
Short Long Term Debt Total	8.4M	10.7M	10.3M	12.5M	16.7M	17.5M
Other Current Liab	648.4K	747.9K	867.1K	1.2M	956.2K	1.0M
Total Current Liabilities	2.5M	2.2M	2.5M	3.1M	4.2M	4.4M
Total Stockholder Equity	29.0M	28.3M	32.6M	30.4M	25.0M	26.2M
Property Plant And Equipment Net	25.3M	28.0M	28.0M	30.6M	32.1M	33.8M
Net Debt	(352.5K)	2.8M	89.0K	6.7M	15.7M	16.5M
Retained Earnings	(2.6M)	(3.7M)	(3.7M)	(6.2M)	(12.0M)	(11.4M)
Cash	8.8M	7.9M	10.2M	5.8M	978.7K	929.8K
Non Current Assets Total	25.5M	28.2M	28.2M	30.9M	32.3M	34.0M
Non Currrent Assets Other	26.9K	26.2K	26.1K	76.6K	57.7K	54.8K
Cash And Short Term Investments	8.8M	7.9M	10.2M	5.8M	978.7K	929.8K
Net Receivables	1.7M	1.9M	2.7M	1.8M	2.2M	2.3M
Common Stock Shares Outstanding	6.8M	7.2M	7.6M	7.7M	7.7M	3.9M
Liabilities And Stockholders Equity	38.7M	40.4M	44.5M	44.9M	43.8M	46.0M
Non Current Liabilities Total	7.2M	9.9M	9.4M	11.4M	14.6M	15.2M
Inventory	2.5M	2.1M	3.1M	6.0M	7.8M	8.2M
Other Current Assets	219.1K	253.6K	268.7K	363.9K	493.9K	247.6K
Other Stockholder Equity	30.9M	31.2M	35.5M	35.8M	36.2M	38.0M
Total Liab	9.7M	12.1M	11.9M	14.5M	18.8M	19.8M
Total Current Assets	13.2M	12.2M	16.3M	14.0M	11.5M	7.0M
Short Term Debt	1.3M	860.8K	920.2K	1.1M	2.1M	2.0M
Intangible Assets	114.6K	95.5K	76.4K	57.3K	38.2K	36.3K
Accounts Payable	572.2K	602.3K	745.0K	790.0K	874.6K	918.3K
Property Plant And Equipment Gross	25.3M	26.8M	42.0M	46.5M	53.5M	56.2M
Other Assets	164.0	406.0	312.0	351.0	1.0	0.95
Long Term Debt	7.1M	8.7M	8.3M	9.2M	10.6M	11.1M
Treasury Stock	(407.9K)	(204.9K)	(188.3K)	(175.4K)	(201.7K)	(211.8K)
Property Plant Equipment	25.3M	28.0M	28.0M	30.6B	35.2B	37.0B
Net Tangible Assets	28.8M	27.8M	32.3M	30.2B	34.8B	36.5B
Retained Earnings Total Equity	979.0K	(1.3M)	(2.6M)	(3.7M)	(3.3M)	(3.1M)
Long Term Debt Total	8.6M	8.4M	7.1M	8.7M	10.0M	10.6M
Capital Surpluse	22.5M	22.7M	31.1M	31.4M	36.1M	19.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:

How To Invest In ImmuCell

Details

Is ImmuCell Stock a good investment?

Details

What is ImmuCell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.49)

Revenue Per Share

2.991

Quarterly Revenue Growth

0.549

Return On Assets

(0.05)

The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ImmuCell Stock Based Compensation vs Investments Analysis

Stock Based Compensation vs Investments

Stock Based Compensation vs Investments Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Investments

ImmuCell fundamental ratios Correlations

ImmuCell Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ImmuCell fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Common Stock Total Equity
Common Stock Total Equity	+ 0.99	Common Stock Shares Outstanding

Inventory	- 0.89	Retained Earnings
Short Term Debt	- 0.85	Retained Earnings
Retained Earnings	- 0.83	Net Debt
Property Plant And Equipment Gross	- 0.81	Retained Earnings
Retained Earnings	- 0.79	Total Current Liabilities
Retained Earnings	- 0.79	Short Long Term Debt Total